NASDAQ:GBT - Global Blood Therapeutics Stock Price, Forecast & News

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Global Blood Therapeutics Inc (NASDAQ:GBT) announced its quarterly earnings data on Wednesday, August, 7th. The company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.96) by $0.05. During the same quarter last year, the business posted ($0.78) EPS. View Global Blood Therapeutics' Earnings History.

Global Blood Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Global Blood Therapeutics.

16 Wall Street analysts have issued 1-year target prices for Global Blood Therapeutics' shares. Their forecasts range from $50.00 to $150.00. On average, they expect Global Blood Therapeutics' stock price to reach $95.60 in the next year. This suggests a possible upside of 34.0% from the stock's current price. View Analyst Price Targets for Global Blood Therapeutics.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 5 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Global Blood Therapeutics.

Media coverage about GBT stock has trended neutral recently, according to InfoTrie. The research firm ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Global Blood Therapeutics earned a coverage optimism score of 0.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Global Blood Therapeutics.

Some companies that are related to Global Blood Therapeutics include BioMarin Pharmaceutical (BMRN), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO) and Jazz Pharmaceuticals (JAZZ).

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Cynosure (CYNO), Exelixis (EXEL), TherapeuticsMD (TXMD), AbbVie (ABBV), Amarin (AMRN), Roku (ROKU) and Intercept Pharmaceuticals (ICPT).

(GBT) raised $102 million in an initial public offering on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Global Blood Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.74%), Perceptive Advisors LLC (9.74%), FMR LLC (8.69%), Bank of America Corp DE (7.82%), Janus Henderson Group PLC (4.98%) and State Street Corp (3.58%). Company insiders that own Global Blood Therapeutics stock include De Dominicis Robert, Deval L Patrick, Joshua Lehrer-Graiwer, Jung Choi, Lesley Ann Calhoun, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Institutional Ownership Trends for Global Blood Therapeutics.

GBT stock was sold by a variety of institutional investors in the last quarter, including Farallon Capital Management LLC, FMR LLC, Franklin Resources Inc., Bank of New York Mellon Corp, State Street Corp, Fernwood Investment Management LLC, Rafferty Asset Management LLC and Sectoral Asset Management Inc. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Deval L Patrick, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Philip A Pizzo, Ted W Love and Tricia Borga Suvari. View Insider Buying and Selling for Global Blood Therapeutics.

GBT stock was acquired by a variety of institutional investors in the last quarter, including Bank of America Corp DE, Janus Henderson Group PLC, Driehaus Capital Management LLC, CIBC Private Wealth Group LLC, Capital World Investors, Crawford Lake Capital Management LLC, Pictet Asset Management Ltd. and California Public Employees Retirement System. View Insider Buying and Selling for Global Blood Therapeutics.

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of GBT stock can currently be purchased for approximately $71.35.

Global Blood Therapeutics has a market capitalization of $4.30 billion. The company earns $-174,190,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis. Global Blood Therapeutics employs 171 workers across the globe.View Additional Information About Global Blood Therapeutics.

The official website for Global Blood Therapeutics is http://www.gbt.com/.

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-741-7700 or via email at [email protected]